SCHEMBL5543397

SCHEMBL5543397

CC(C)N1C(=O)[N]c2cc(N(C)C)ccc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 3/20 0.34
HSD17B10 Q99714 3/20 0.34
HPGD P15428 2/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TERT O14746 1/20 0.33
APP P05067 1/20 0.33
ELANE P08246 1/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PSMB5 P28074 1/20 0.32
IP6K1 Q92551 1/20 0.32
SYK P43405 1/20 0.32
IDO1 P14902 1/20 0.32
TDO2 P48775 1/20 0.32
IDO2 Q6ZQW0 1/20 0.32
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542560 0.79 ALDH1A1 (0.46) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL5546458 0.78 POLB (0.35) ALDH1A1GAAKMT2A
SCHEMBL4813307 0.76 SMN1; SMN2 (0.38) ALDH1A1KDM4EMAPTNPSR1SMN1; SMN2
SCHEMBL22035258 0.60 ALDH1A1 (0.46) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL2270251 0.59 ALDH1A1 (0.46) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL27750062 0.58 KMT2A (0.55) ALDH1A1KDM4EHPGDMAPTMEN1
SCHEMBL16143349 0.58 TERT (0.46) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL9514250 0.58 ALDH1A1 (0.59) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL9769393 0.58 ALDH1A1 (0.59) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL2270707 0.56 ALDH1A1 (0.46) ALDH1A1KDM4EHSD17B10HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885KDM4E 4854/4885HSD17B10 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.